Showing 1571-1580 of 1735 results for "".
- CooperVision to Spotlight Myopia Control and Management Advocacy at ESCRShttps://modernod.com/news/coopervision-to-spotlight-myopia-control-and-management-advocacy-at-escrs/2481809/CooperVision will spotlight advancing myopia control and management as standard of care across all ocular health sectors at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference in Vienna. On September 7, a thought leadership panel will be held
- Bausch + Lomb Launches Infuse Multifocal Silicone Hydrogel Contact Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-infuse-multifocal-silicone-hydrogel-contact-lenses-in-the-united-states/2481649/Bausch + Lomb announced the US launch of Bausch + Lomb Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a new material infused with ProBalance Technology for all-day comfort and the company’s '3-Zone Progressive' design,
- Bausch + Lomb Announces Leadership Changeshttps://modernod.com/news/bausch-lomb-announces-leadership-changes/2481644/Bausch + Lomb announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the comp
- Partnership Agreement Between Mireca and Graybug Terminatedhttps://modernod.com/news/partnership-agreement-between-mireca-and-graybug-terminated/2481631/Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases. As part of the termination, all intellectual property rights that
- International Sports Vision Association Launches "Ask a Sports Vision Expert" Featurehttps://modernod.com/news/international-sports-vision-association-launches-ask-a-sports-vision-expert-feature/2481622/A growing body of evidence confirms that visual abilities can be strengthened and enhanced by means of appropriate visual training. Sports vision, the science of helping athletes reach peak levels of performance through enhancement of visual skills, is becoming more important in training for all
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- Harrow Announces Appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilancehttps://modernod.com/news/harrow-announces-appointment-of-mark-mannebach-phd-rph-as-head-of-regulatory-affairs-and-pharmacovigilance/2481449/Harrow announced the appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the company’s portfolio of new and existing products. Dr. Mannebach
- Pixium Vision Completes Implantations in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-completes-implantations-in-the-european-pivotal-trial-primavera/2481297/Pixium Vision SA announced the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in geographic atrophy. A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline
- Graybug and CalciMedica Enter Into Definitive Merger Agreementhttps://modernod.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intr
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered